Maxim raised the firm’s price target on INmune Bio (INMB) to $30 from $22 and keeps a Buy rating on the shares. The company’s announcement related to positive data for a stem cell-based therapy called “CORDstrom” for recessive dystrophic epidermolysis bullosa – RDEB – offers investors a BLA-ready asset “for free”, the analyst tells investors in a research note. Given the unmet need in RDEB, the shifting sentiment at the regulatory level for stem cell therapies, and the stage of the CORDstrom program, it could become a significant value driver for INmune, Maxim adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio opens Phase II in high dose cohort of INKmune trial
- Inmune Bio’s Strategic Advancements and Promising Clinical Trials Justify Buy Rating
- INmune Bio price target raised to $23 from $22 at Scotiabank
- Inmune Bio Secures License Agreement for CORDStrom Data
- Inmune Bio Completes Phase 2 Trial for CORDStrom
Questions or Comments about the article? Write to editor@tipranks.com